Regulatory
HIGHTrigger: If DCGI approval is delayed materially beyond Q1 FY27, the ₹80-90 Cr semaglutide contribution and 20%+ domestic growth guidance are at risk
Monitor: regulatory
Natco Pharma Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +44.0%Strong12w Streak
In , Natco Pharma Ltd (Pharma - Formulators) is outperforming Nifty 500 with +44.0% relative strength. Fundamentals: Strong. On a 12-week streak.
Natco Pharma Ltd Key Facts
- PE Ratio
- 12.6x
- Market Cap
- ₹19,626 Cr
- PAT Growth YoY
- +14%
- Revenue Growth YoY
- +36%
- OPM
- 25.0%
- RS vs Nifty 500
- +44.0%
PE: Early ExpansionAvoid
What's Happening
🚫No earnings growth, no valuation discount — limited upside
🌐FII stake decreased 3.4% this quarter
💰Trading 229% below estimated fair value — significant discount
Key Risks
1. Regulatory
HIGH2. Regulatory
MEDIUM3. Geopolitical
MEDIUMKey Numbers
PAT Growth YoY
+14%
Stable
Revenue YoY
+36%
Stable
Operating Margin
25.0%
+1700 bps YoY
PE Ratio
12.6
Current Price
₹1,096
Dividend Yield
0.55%
Fundamental Score
63/100
Strong
3Y PAT CAGR
+80%
Market Cap
21.0K Cr
Valuation
Significantly Undervalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
What Are the Key Risks for Natco Pharma Ltd?
Earnings deceleration risks from management commentary
Regulatory
MEDIUMTrigger: Exclusivity-period PAT margins (40-50%) vs base-business margins (27-32%) represent a structural volatility in earnings quality
Monitor: regulatory
Geopolitical
MEDIUMTrigger: South Africa's ZAR/INR exchange rate volatility and sub-Saharan Africa's macroeconomic fragility could reduce reported PAT contribution in INR terms
Monitor: geopolitical
Regulatory
LOWTrigger: NCLT and competition authority timelines are uncertain; the demerger value-unlock thesis is time-sensitive for FY27 stock performance
Monitor: regulatory
What Is Natco Pharma Ltd's Management Saying?
Key quotes from recent conference calls
“We expect to be in the first wave of generic launches in India post-March 2026. DCGI approval is still pending as of the call date [Risk (regulatory): HIGH]”
“EBITDA margin contracted year-on-year as the base included partial Revlimid exclusivity premium in Q4 FY25. Pomalidomide exclusivity launched in March 2026 should partially offset Revlimid expiry impact through Q1 FY27 [Risk (regulatory): MEDIUM]”
“The acquisition, valued at approximately $226 million (R4 billion), was completed on November 11, 2025. Adcock Ingram operates across South Africa, Sub-Saharan Africa, India, and select international markets [Risk (geopolitical): MEDIUM]”
“The demerger is expected to be completed by October-November 2026, subject to NCLT and regulatory approvals [Risk (regulatory): LOW]”
How Fast Is Natco Pharma Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +36% | +32% | Stable |
| PAT (Net Profit) | +14% | +80% | Stable |
| OPM | 25.0% | +1700 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Natco Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Natco Pharma Ltd's latest quarterly results?
Natco Pharma Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +14.4% (stable)
- Revenue Growth YoY: +36.2%
- Operating Margin: 25.0% (volatile)
Is Natco Pharma Ltd's profit growing or declining?
Natco Pharma Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +14.4% (latest quarter)
- PAT Growth QoQ: -70.8% (sequential)
- 3-Year PAT CAGR: +80.0%
- Trend: Stable — consistent growth pattern
What is Natco Pharma Ltd's revenue growth trend?
Natco Pharma Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +36.2%
- Revenue Growth QoQ: -52.5% (sequential)
- 3-Year Revenue CAGR: +31.6%
How is Natco Pharma Ltd's operating margin trending?
Natco Pharma Ltd's operating margin is volatile.
- Current OPM: 25.0%
- OPM Change YoY: +17.0% basis points
- OPM Change QoQ: -17.0% basis points
What is Natco Pharma Ltd's 3-year profit and revenue CAGR?
Natco Pharma Ltd's long-term compounding rates
- 3-Year Profit CAGR: +80.0%
- 3-Year Revenue CAGR: +31.6%
Is Natco Pharma Ltd's growth accelerating or decelerating?
Natco Pharma Ltd's earnings growth is stable with weakening on a sequential basis.
- YoY Acceleration: +37.8% bps
- Sequential Acceleration: -57.9% bps
- Note: YoY and QoQ trends are diverging — worth monitoring
- Margin Warning: Operating margins are under pressure
What is Natco Pharma Ltd's trailing twelve month (TTM) performance?
Natco Pharma Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹2,000 Cr
- TTM PAT Growth: -16.5% YoY
- TTM Revenue: ₹5,000 Cr
- TTM Revenue Growth: +6.6% YoY
- TTM Operating Margin: 40.7%
Is Natco Pharma Ltd overvalued or undervalued?
Natco Pharma Ltd appears significantly undervalued based on our fair value analysis.
- Valuation Signal: Significantly Undervalued
- Current PE: 12.6x
- Price-to-Book: 2.3x
What is Natco Pharma Ltd's current PE ratio?
Natco Pharma Ltd's current PE ratio is 12.6x.
- Current PE: 12.6x
- Market Cap: 19.6K Cr
- Dividend Yield: 0.55%
How does Natco Pharma Ltd's valuation compare to its history?
Natco Pharma Ltd's current PE is 12.6x.
- Current PE: 12.6x
- Valuation Assessment: Significantly Undervalued
What is Natco Pharma Ltd's price-to-book ratio?
Natco Pharma Ltd's price-to-book ratio is 2.3x.
- Price-to-Book (P/B): 2.3x
- Book Value per Share: ₹483
- Current Price: ₹1096
Is Natco Pharma Ltd a fundamentally strong company?
Natco Pharma Ltd is rated Strong with a fundamental score of 63.4/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +36.2% (10% weight)
- PAT Growth YoY: +14.4% (10% weight)
- PAT Growth QoQ: -70.8% (10% weight)
- Margins stable (10% weight)
Is Natco Pharma Ltd debt free?
Natco Pharma Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹279 Cr
What is Natco Pharma Ltd's return on equity (ROE) and ROCE?
Natco Pharma Ltd's return ratios over recent years
- FY2023: ROCE 18.0%
- FY2024: ROCE 30.0%
- FY2025: ROCE 33.0%
Is Natco Pharma Ltd's cash flow positive?
Natco Pharma Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹2,000 Cr
- Free Cash Flow (FCF): ₹261 Cr
- CFO/PAT Ratio: 90% (strong cash conversion)
What is Natco Pharma Ltd's dividend yield?
Natco Pharma Ltd's current dividend yield is 0.55%.
- Dividend Yield: 0.55%
- Current Price: ₹1096
Who holds Natco Pharma Ltd shares — promoters, FII, DII?
Natco Pharma Ltd's shareholding pattern (Mar 2026)
- Promoters: 49.4%
- FII (Foreign): 17.4%
- DII (Domestic): 5.5%
- Public: 27.7%
Is promoter holding increasing or decreasing in Natco Pharma Ltd?
Natco Pharma Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 49.4% (Mar 2026)
- Previous Quarter: 49.5% (Dec 2025)
- Change: -0.07% (decreasing — worth monitoring)
How long has Natco Pharma Ltd been outperforming Nifty 500?
Natco Pharma Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Is Natco Pharma Ltd a new momentum entry or an established outperformer?
Natco Pharma Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
What are the key risks in Natco Pharma Ltd?
Natco Pharma Ltd has 4 key risks worth monitoring
- [HIGH] Regulatory — If DCGI approval is delayed materially beyond Q1 FY27, the ₹80-90 Cr semaglutide contribution and 20%+ domestic growth guidance are at risk
- [MEDIUM] Regulatory — Exclusivity-period PAT margins (40-50%) vs base-business margins (27-32%) represent a structural volatility in earnings quality
- [MEDIUM] Geopolitical — South Africa's ZAR/INR exchange rate volatility and sub-Saharan Africa's macroeconomic fragility could reduce reported PAT contribution in INR terms
- [LOW] Regulatory — NCLT and competition authority timelines are uncertain; the demerger value-unlock thesis is time-sensitive for FY27 stock performance
What did Natco Pharma Ltd's management say in the latest earnings call?
In Q4 FY26, Natco Pharma Ltd's management highlighted
- "We expect to be in the first wave of generic launches in India post-March 2026. DCGI approval is still pending as of the call date [Risk (regulatory)..."
- "EBITDA margin contracted year-on-year as the base included partial Revlimid exclusivity premium in Q4 FY25. Pomalidomide exclusivity launched in March..."
- "The acquisition, valued at approximately $226 million (R4 billion), was completed on November 11, 2025. Adcock Ingram operates across South Africa, Su..."
Is Natco Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Natco Pharma Ltd may be worth studying
- Earnings growing at +14.4% YoY
- Valuation: appears significantly undervalued
- Cash flow is positive — CFO ₹2,000 Cr
What is the investment thesis for Natco Pharma Ltd?
Natco Pharma Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +36.2% YoY
- Appears significantly undervalued
Risk Factors (Bear Case)
- Margins under pressure
- Key risk: Regulatory
What is the future outlook for Natco Pharma Ltd?
Natco Pharma Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Significantly Undervalued
- Key Risk: Regulatory
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.